Mayo Clinic: management of patients with statin intolerance

References

• Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J. Am. Coll. Cardiol. 40(3), 567–572 (2002). ▪ Clinical advisory defining myopathy, myalgia, myositis and rhabdomyolysis, and reviewing pertinent safety data.
   Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 97(8A), 89C–94C (2006). ▪ Detailed review and discussion addressing statin safety by system, including the liver, muscles, kidneys and neurologic disorders.
   Google Scholar
• Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med. 24(5), 258–272 (2001).
   Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 289(13), 1681–1690 (2003).
   Google Scholar
• Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab. Syndr. Obes. 4, 155–166 (2011).
   Google Scholar
• Molokhia M, Mckeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS ONE 3(6), e2522 (2008).
   Google Scholar
• Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: a review. Muscle Nerve doi: 10.1002/mus.23854 (2013) (Epub ahead of print). ▪▪ Provides up‑to‑date information on anti‑HMG‑CoA reductase‑associated myopathy.
   Google Scholar
• Davidson MH, Robinson JG. Safety of aggressive lipid management. J. Am. Coll. Cardiol. 49(17), 1753–1762 (2007).
   Google Scholar
• Athyros VG, Tziomalos K, Gossios TD et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376(9756), 1916–1922 (2010).
   Google Scholar
• Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403–414 (2005). ▪ The original PRIMO conditions study, which is widely quoted throughout the literature when referring to the incidence of muscular symptoms in patients on statin therapy.
   Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Intern. Med. 150(12), 858–868 (2009). ▪ Comprehensive review of pertinent information for clinicians of statin‑related myopathy, including summaries of relevant trials.
   Google Scholar
• Mancini GB, Baker S, Bergeron J et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can. J. Cardiol. 27(5), 635–662 (2011). ▪▪ Detailed review of statin intolerance, with a particularly thorough section describing statin‑related signs and symptoms, and reviewing the associated study data.
   Google Scholar
• Vandenberg BF, Robinson J. Management of the patient with statin intolerance. Curr. Atheroscler. Rep. 12(1), 48–57 (2010).
   Google Scholar
• Silva M, Matthews ML, Jarvis C et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin. Ther. 29(2), 253–260 (2007).
   Google Scholar
• Marot A, Morelle J, Chouinard VA, Jadoul M, Lambert M, Demoulin N. Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature. Acta Clin. Belg. 66(2), 134–136 (2011).
   Google Scholar
• Vladutiu GD, Simmons Z, Isackson PJ et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34(2), 153–162 (2006).
   Google Scholar
• Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med. 359(8), 789–799 (2008).
   Google Scholar
• Bays H. Statin safety: an overview and assessment of the data – 2005. Am. J. Cardiol. 97(8A), 6C–26C (2006).
   Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am. J. Cardiol. 97(8A), 52C–60C (2006).
   Google Scholar
• Kashani A, Phillips CO, Foody JM et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114(25), 2788–2797 (2006).
   Google Scholar
• Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin. Ther. 29(8), 1761–1770 (2007).
   Google Scholar
• Mensink RP, Katan MB. Effect of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of lowdensity and high-density lipoprotein cholesterol in healthy women and men. N. Engl. J. Med. 321(7), 436–441 (1989).
   Google Scholar
• Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr. Res. 2008, 52 (2008).
   Google Scholar
• Estruch R, Ros E, Salas-Salvado J et al. Primary prevention of cardiovascular disease with a mediterranean diet. N. Engl. J. Med. 368(14), 1279–1290 (2013).
   Google Scholar
• De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99(6), 779–785 (1999).
   Google Scholar
• Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 56(2), 320–328 (1992).
   Google Scholar
• Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis 215(1), 23–29 (2011).
   Google Scholar
• Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 49(23), 2231–2237 (2007).
   Google Scholar
• Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch. Intern. Med. 165(22), 2671–2676 (2005).
   Google Scholar
• Zhang H, Plutzky J, Skentzos S et al. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 158(7), 526–534 (2013).
   Google Scholar
• Glueck CJ, Aregawi D, Agloria M et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin. Ther. 28(6), 933–942 (2006).
   Google Scholar
• Piamsomboon C, Laothavorn P, Saguanwong S et al. Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J. Med. Assoc. Thai. 85(3), 297–300 (2002).
   Google Scholar
• Juszczyk MA, Seip RL, Thompson PD. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev. Cardiol. 8(4), 197–199 (2005).
   Google Scholar
• Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am. J. Cardiol. 103(3), 393–394 (2009).
   Google Scholar
• Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am. J. Cardiol. 101(12), 1747–1748 (2008).
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19), 2409–2415 (2003).
   Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr. Med. Res. Opin. 23(9), 2183–2192 (2007).
   Google Scholar
• Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am. J. Cardiovasc. Drugs 10(5), 305–314 (2010).
   Google Scholar
• Childress L, Gay A, Zargar A, Ito MK. Review of red yeast rice content and current Food and Drug Administration oversight. J. Clin. Lipidol. 7(2), 117–122 (2013).
   Google Scholar
• Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 308(6925), 367–372 (1994).
   Google Scholar
• Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-ana lysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753), 1670–1681 (2010).
   Google Scholar